Strategic funding ThirtyFiveBio recently closed a bridge financing round with strategic investment from AbbVie Ventures alongside existing and new investors, signaling strong interest from big pharma and potential collaboration or licensing opportunities for GPR35-related GI therapies.

Big pharma interest The involvement of AbbVie Ventures in the latest funding round highlights a credible pathway for partnerships, co-development, or potential acquisition discussions as the company advances its first-in-class GPR35 inhibitors.

Clinical focus With a focus on small-molecule GPR35 inhibitors for ulcerative colitis and other GI diseases, there is a clear market need for novel GI therapeutics, presenting opportunities for pharma sponsors, co-development deals, and research collaborations.

Early-stage traction Revenue under one million and a seed-like funding level suggest ThirtyFiveBio is in early R&D-to-valuation mode, offering opportunities for grant support, strategic partnerships, or milestone-driven collaborations to accelerate development.

Regional foothold Based in Oxford with a biotech focus and a lean team, ThirtyFiveBio is well-positioned for EU and UK biotech partnerships, academic collaborations, and access to European translational research networks to advance preclinical and early clinical programs.